Role of Estrogens in osteoclastogenesis and immunomodulation of T cells. - ND

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点开始时间: 2009年3月17日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•a.BMD T-score equal or lower -2.5 S.D. according toWHO (WHO Technical Report Series nr 843 ?Assessment of fracture risk and the application to screening for post,enopausal osteoporosis?, 1994). With or without fractures
•All the women will be in postmenopausal period since at least one year
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•a.legal inhability to give the consent
•b.secondary osteoporosis
•c.threapy with calcium and vitamin D, thyroid hormones, corticosteroids, estrogens, bisphosphonastes, parthyroid hormone, fluorures, strontium ranelate and raloxifene in the last six months
•d.Immunosuppressive therapy (ciclosporin, azathyoprine) in the last year
•e.presence of previous adverse events with the drugs in study
•f.previous history of cancer
•g.previous histoy of venous, retinic or pulmonary tromboembolism, or othero coaugulopathies
•h.history of hepatopathy
•i.histerectomy

发起方

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO